Cancer News and Research

Latest Cancer News and Research

CINJ receives grant to support its Breast Surgery Fellowship Program

Receiving a boost to support its Breast Surgery Fellowship Program, The Cancer Institute of New Jersey has been awarded a $75,000 grant from The Breast Cancer Alliance for academic year 2012-2013.

9 Jan 2012

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Health Discovery Corporation, a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. for laboratory developed tests in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC.

9 Jan 2012

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences, Inc. announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.

9 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

9 Jan 2012

Presidio completes PPI-668 Phase 1a study on hepatitis C

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.

9 Jan 2012

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.

9 Jan 2012

BioCells opens new franchise headquartered in Campinas, Brazil

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that Biocordcell Argentina S.A. is opening a new franchise headquartered in Campinas, Brazil, a city of more than one million in the state of Sao Paulo.

9 Jan 2012

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

SFJ Pharma Ltd. II announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

9 Jan 2012

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets.

9 Jan 2012

BerGenBio completes $8.8M Series A financing round

BerGenBio AS, an emerging oncology biopharma company, today announced it has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic.

9 Jan 2012

Many parents share BRCA1/A2 test results with their children

A new study has found that when parents get tested for breast cancer genes, many of them share their results with their children, even with those who are very young. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that most parents think that their children are not distressed when they learn about the test results.

9 Jan 2012

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection.

9 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

MPIIB, QIAGEN partner to develop latent TB diagnostic test

QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.

From QIAGEN Manchester Limited 9 Jan 2012

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

HCA issues commitment to offer full support to PIP breast implant patients

Last Friday the MHRA advised that they found no evidence to support routine removal of PIP breast implants and they recommended that any patients who were concerned about their implant should seek clinical advice from their consultant surgeon.

8 Jan 2012

Vinegar may easily detect cervical cancer

Vinegar may be more useful than realised. Its could offer the ability to find precancerous lesions in the cervix and potentially save thousands of women’s lives say researchers.

8 Jan 2012

Great Prostate Cancer Challenge 5K Race to take place in Fort Myers on Jan. 28

Lace up your sneakers and join Florida Urology Physicians and ZERO — The Project to End Prostate Cancer on Saturday, January 28, 2012 for the Great Prostate Cancer Challenge 5K Race in Fort Myers. The Great Prostate Cancer Challenge is America's premier men's health event series, taking place in 33 cities in 2012.

7 Jan 2012

Cancer News and Research

Latest Cancer News and Research

CINJ receives grant to support its Breast Surgery Fellowship Program

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Presidio completes PPI-668 Phase 1a study on hepatitis C

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

BioCells opens new franchise headquartered in Campinas, Brazil

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

BerGenBio completes $8.8M Series A financing round

Many parents share BRCA1/A2 test results with their children

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

MPIIB, QIAGEN partner to develop latent TB diagnostic test

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Positive results from BioCryst's BCX4208 Phase 2b study on gout

HCA issues commitment to offer full support to PIP breast implant patients

Vinegar may easily detect cervical cancer

Great Prostate Cancer Challenge 5K Race to take place in Fort Myers on Jan. 28

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in